Variables | N | 3-yr PFS(%) [95%CI] | p | 3-yr OS(%) [95%CI] | p |
---|---|---|---|---|---|
Gender | |||||
Female | 14 | 62 [26–84] | 85 [52–96] | ||
Male | 18 | 14 [2–35] | 0.01 | 47 [20–71] | 0.19 |
Stage of disease | |||||
Localized | 13 | 73 [37–90] | 84 [49–96] | ||
Metastatic | 19 | 7 [1–28] | 0.0004 | 43 [15–69] | 0.15 |
SUVmax | |||||
<17 | 26 | 41 [20–60] | 72 [44–87] | ||
≥17 | 6 | 0 [0–0] | 0.001 | 21 [1–60] | 0.004 |
SUVpeak | |||||
<12.5 | 26 | 36 [17–56] | 72 [44–87] | ||
≥12.5 | 6 | 0 [0–0] | 0.002 | 0 [0–0] | <0.001 |
SUVmean40% | |||||
<8.5 | 25 | 44 [23–63] | 71 [43–87] | ||
≥8.5 | 7 | 0 [0–0] | 0.017 | 34 [5–69] | 0.018 |
SUV: Standardized Uptake Value; PFS: Progression Free Survival; OS: Overall Survival; HR: Hazard Ratio; CI: Confidence Interval.